Peking University People's Hospital: Osteosarcoma trials

The registry lists 23 Osteosarcoma studies with Peking University People's Hospital as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 9No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic OsteosarcomaRecruitingNCT07479732Phase 1/2
• B7-H3 NIR Imaging for Osteosarcoma SurgeryRecruitingNCT06778603Phase 1/2
• Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical StudyNot yet recruitingNCT06776198
• Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of OsteosarcomaRecruitingNCT06714383Phase 2
• Soluble B7-H3 as a Biomarker for OsteosarcomaRecruitingNCT05942456
• the Exploration of MTAP Deletion in Osteosarcoma by ImmunohistochemistryActive, not recruitingNCT07593573
• Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis AssessmentActive, not recruitingNCT06850506
• Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)CompletedNCT05277480Phase 2
• Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory OsteosarcomaSuspendedNCT04824352Phase 2
• TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN LossStatus unknownNCT04690725Phase 1/2
• Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory OsteosarcomaCompletedNCT04690231Not applicable
• Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective StudyCompletedNCT04546243
• Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade OsteosarcomaStatus unknownNCT04351308Phase 2
• Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced OsteosarcomaWithdrawnNCT04044378Phase 1/2
• Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OSCompletedNCT03997747
• Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and CamrelizumabStatus unknownNCT03919539
• Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity OsteosarcomaCompletedNCT03909776Not applicable
• PD-L1 Expression in Advanced OsteosarcomaStatus unknownNCT03582527
• The Osteosarcoma Biobank in Peking University People's HospitalStatus unknownNCT03362086
• Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and SacrumStatus unknownNCT03360760Not applicable
• Apatinib Plus Anti-PD1 Therapy for Advanced OsteosarcomaCompletedNCT03359018Phase 2
• Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade OsteosarcomaStatus unknownNCT03358628
• Epigenetic Biomarker for OsteosarcomaStatus unknownNCT03336554